The announcement is based on early data from a phase 2a clinical trial that involved 202 non-hospitalized COVID-19 patients. The pill, molnupiravir, was well tolerated by the participants and significantly reduced their viral load.
The drugmakers are continuing to study the drug in phase 2/3 clinical programs, which will test it in both outpatient and hospital settings.
More articles on pharmacy:
Moderna vaccine causing delayed rash in some recipients, small study says
COVID-19 drug doesn’t benefit patients with mild illness, study finds
Drugmakers studying how to administer COVID-19 vaccines without a needle
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
